Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in INS?
Instem Plc: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Huge jump in SEND orders helps Instem swing to a first-half profit; shares higher

Instem generated revenues of £10.5mln (H1 17: £10.3mln) in the opening six months of 2018, reporting a profit before tax of £0.1mln (H1 17: loss of £0.6mln)
fda button
INVESTMENT OVERVIEW: INS The Big Picture
Shares have more than doubled so far this year

Instem PLC (LON:INS) saw its shares rise on Monday as the developer of software used by the life sciences industry to collate and transmit data swung to a profit in the first half of the year.

The major growth driver was its SEND platform, for which it received 75 orders in the six months ended June 30 – three times as many orders as it received for the same period last year (23). In early afternoon trading, Instem shares were 0.7% higher at 302p.

READ: Instem secures US$750k contract with Fortune 500 heavyweight

SEND stands for Standard for the Exchange of Nonclinical Data and is a protocol set up by the US Food and Drug Administration. It ensures that companies present data in a consistent format.

Among the contract-wins was one with a top five global, non-clinical contract research organisation, worth more than £1.7mln over the next two years.

Another big client, a “top-five preclinical CRO”, sent over £0.4mln worth of business Instem’s way in the first half.

The company also has its Provantis and Samarind products, both of which are available via the cloud. A Fortune 500 company adopted the Samarind RMS solution for its worldwide medical products regulatory tracking system.

Boss happy

“We are very pleased with the performance of the business during H1 2018, with regulatory requirements delivering the expected significant increase in demand for our technology-enabled outsourced services,” said chief executive Phil Reason.

“Growth was also particularly strong in the Asia-Pacific region, with bookings up over 60% on the prior year, primarily attributable to the continuing funding of Pharmaceutical Research & Development by the Chinese government."

He added: “With increasing momentum in the business from recent contract wins and the growing pipeline, we are confident about the outlook for the group for the rest of 2018 and beyond.”

Improved margins

Instem generated revenues of £10.5mln (H1 17: £10.3mln) in the opening six months of 2018, reporting a profit before tax of £0.1mln (H1 17: loss of £0.6mln).

Excluding various one-off costs and currency movements, adjusted pre-tax profits jumped to £0.8mln (H1 17: £0.1mln). Last year’s restructuring and a more favourable sales mix helped to boost margins.

Net operating cash inflows of £1.6mln (H1 17: outflow of £1.4mln) allowed cash balances to rise to £3.7mln (H1 17: £1.2mln).

The stock has more than doubled so far this year, reflecting the strong performance year-to-date. Shares were steady at 300p on Monday, having opened the year at 143p.

Analyst praises results

“The H1 performance provides the group with a very solid platform for delivery of our (and consensus) estimates for the full year,” said Progressive Equity analyst Gareth Evans.

“Revenue is tracking to historic patterns, and the H2 required EBITDA result appears highly achievable, when compared to prior years, and given the normal seasonality in the business.

“Further, the group has achieved this strong result despite ongoing investment in, and growth of, its capacity – across the group, but especially in relation to SEND and SEND services, where there appears to be clear growth already being achieved, but very material scope for further expansion given the scale of the relevant markets.

“Overall, H1 2018 is a strong signal of current performance, but also bodes very well for medium and longer-term delivery.”

 -- Adds share price and analyst comment --

View full INS profile View Profile

Instem Plc Timeline

Related Articles

Person watching TV on a smartphone
October 01 2018
"The business model is proving solid and with a higher percentage of revenues coming from recurrent subscriber-based licence fees, we are steadily reaching the point of profitability," said chief executive, Jose Luis Vazquez.
Dancing Sikh
April 12 2018
With 4bn tickets sold each year for Bollywood films, it is little wonder that India is taking an interest in GrooveME's hologram technology but that same technology can bring a bit of India to places such as Thetford
keyboard
July 17 2018
KeyDrive develops and operates software platforms to operate domain names

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use